TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in number of Carbon Monoxide Alarm hazards
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of Electrical Fire and Shock hazards
Endpoint domain: Adverse events/effects
Primary endpoint: regional brain activation in the ventromedial prefrontal cortex (vmPFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain creatine change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perioperative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: adverse brain function events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in static and dynamic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related rebleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Delta CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with MG-ADL decreased by ≥2
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnosis of Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postpartum depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily mood changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-operative Pain Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Pain Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Pain Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term Post-operative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Stress Response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Volume of thalamic nuclei
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in the concentration of oxyhemoglobin during the task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change in the concentration of deoxyhemoglobin during the task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post Prandial Triglyceride Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oswestry disability index (ODI) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pediatric nurses' knowledge in newborn blood screening tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of Overall Anxiety Severity and Impairment Scale during the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of Overall Depression Severity and Impairment Scale during the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of Chinese Perceived Stress Scale during the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in mean change of systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of participants using cesarean section delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of mental diseases and metabolic dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Isokinetic Upper Limb Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients receiving systemic anticancer treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensorial Assessment-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite learning score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Hemoglobin A1c (HbA1c) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gross grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with VR-related side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in trait-anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in state-anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of chronic non-specific arousal (stress)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of near-miss ordering errors
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction of the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants enrolled and retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent error for wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shot Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Tone Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Stiffness Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Elasticity Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 Yorkshire Rehabilitation Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IBD activity triggering a treatment change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total coronary plaque burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coronary high-risk plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion of 3-survey patient-reported outcome measure at 6-week follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Jefferson Scale of Patient's Perceptions of Physician Empathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perioperative cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of Participants who Complete ORCHID
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Caries severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance rate of phlebotomy-free complete hematologic response (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive predictive value of CTCs counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Total Weight Loss (TWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (operation-related complications and radiation side effects)
Endpoint domain: Adverse events/effects
Primary endpoint: Blood loss measured by hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain during cervical dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of Participants With HIV Transmission Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rotator cuff retear rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: count of sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: motility of sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: morphology of sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cutaneous Disease Area and Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Defined Daily Doses of Antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Kidney-intact disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Retinal Amyloid-β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in student referrals to mental health interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change on Peabody Developmental Scales - Second Edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with available NGS testing at diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients with available NGS re-testing after progression
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ankle Joint Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ankle Joint Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: EORTC QLQ-CR29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dynamics of mitochondrial activity neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positron emission tomography/computed tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS scores of visceral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of emotionality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients Achieving Optimal Platelet Reactivity (OPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Any bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: 90 day complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate Based on Investigator Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inflammatory and Pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean serum TNF-alpha concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean serum IL-6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rs1980422-related single-nucleotide polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local-field potentials changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Firing rate changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes from baseline physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in SANDE Questionnaire Frequency score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in corneal fluorescein staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with adrenal insufficiency
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with safety findings determined by laboratory testing
Endpoint domain: Adverse events/effects
Primary endpoint: Home Exercise Program adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Uptake of hrHPV self-test in community
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Coverage of hrHPV self-test in community
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Uptake of VIA or Pap-smear of eligible women
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Garadacimab Induced Anti Drug Antibodies (ADAs) in Plasma
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of interviews
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion of questionnaire
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion of face validity assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of liver function tests abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change from baseline in forced vital capacity (FVC) in mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Annual rate of decline in FVC in mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in HRCT fibrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to awake from anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Seroma
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Skin necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Enterocutaneous fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Mesh infection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving HiSCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in urticaria activity score (UAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of exophthalmos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of the surgical technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CLDEQ-8 scores at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Contact lens wear time at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with non-carious cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cognitive Processing Speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in B12 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TNF alfa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Responders Using the Global Aesthetic Improvement Scale (GAIS) at Month 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency and severity of sexual dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Experienced One or More Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Study Intervention Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of fracture displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete response rate (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Airway inflammation characteristics and changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical efficacy measured through GERD-HRQL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global health status / Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gastric neoplasia miss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adjustment Disorder New Module Self Report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalized Anxiety Disorder Questionnaire - 7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of treatment in reducing melasma severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of participants experiencing Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing Medically-Attended Adverse Events (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum coenzyme Q10 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip Disability and Osteoarthritis Outcome Score (HOOS) ADL function subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MRI T2 relaxation time mapping of hip articular cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI T1rho relaxation time mapping of hip articular cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times in the Approach/Avoidance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to cease of new lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve minimal therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of methylprednisolone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NASA-TLX (NASA Task Load Index)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: QUEST 2.0 (Quebec User Evaluation of Satisfaction with assistive Technology)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chest Compression Fraction (CCf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune Checkpoint levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Clinical Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Any Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline to 12 Months in Lumbar Spine BMD Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hospitalisations for AECOPD
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum Plasma Concentration (Cmax) of Sotorasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Sotorasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of sedative drugs administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with Recurrent AF or AFlutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of AF or AFlutter Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiovascular Risk Factors changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum clot firmness (MCF via FIBTEM A10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with key symptoms associated with the wearing off effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal goal achievement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Feasibility of hydrogen administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of hydrogen administration
Endpoint domain: Adverse events/effects
Primary endpoint: Upper extremity disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes